This $299,889 firm fixed price definitive contract was awarded by the National Institutes of Health's National Institute of Allergy and Infectious Diseases to Esper Biosciences Inc. for hepatitis C diagnostics using nanopore field-effect sensors. The contract is being performed in Ithaca, NY from September 2021 through September 2023. It falls under a Small Business Innovation Research solicitation issued by the NIH and Centers for Disease Control and Prevention seeking proposals for innovative solutions aligned with agency missions, such as in infectious diseases and public health preparedness. As a total small business set-aside, the solicitation and resulting contract aim to stimulate technological innovation through research and development conducted by small firms.
Generated 12/29/23, 3:53 PM